Trial Comparing Radical Radiotherapy to Prostate Only VS Prostate And Pelvic Lymph Nodes in Intermediate And High Risk Prostate Cancer

Inclusion Criteria: * Histologically-proven prostatic adenocarcinoma. * Risk stratification from intermediate to very high risk will be included according to NCCN guide lines September 5, 2019 version 4.2019: * Intermediate risk: T2b or T2c and/or GS =7 and/or PSA \>10-20. Both the favorable intermediate (1 intermediate risk factor (IRF) and Grade Group 1 or 2 and \<50% biopsy core positive) and unfavorable intermediate risk (2 or 3 IRFs and/or Grade Group 3 and/or ≥50% biopsy cores positive) will be included. * High risk: T3a or PSA \>20 or Grade Group 4 or 5, not very high risk. * Very high risk: T3b-4, primary gleason pattern 5 OR \>4 cores with grade group 4 or 5 * N stage: N0 * M Stage: M0 * Performance Status: PS 0-2 Exclusion Criteria: * Low risk prostate cancer * Histologies other than adenocarcinoma * Patients with significant comorbidities might affect treatment completion and follow up * Previously received pelvic radiotherapy * Patients with metastatic disease * Poor performance status (PS ≥ 3)